Matinas BioPharma Holdings, Inc. Matinas BioPharma Holdings, Inc.

close
  • Home
  • LNC Technology
    • LNC Platform
    • MAT2203
    • MAT2501
  • About Us
    • Company Overview
    • Leadership
    • News
  • Investors
    • Investors Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Contact

Press Releases

Investors

Investors

  • Investors Overview
  • News & Events
    • News & Events Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Company Info Overview
    • Executive Team
    • Presentations
    • Contacts
  • Financial Info
    • Financial Info Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • SEC Filings Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
News & Events

News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
  • News & Events

  • News & Events Overview
  • Press Releases
  • IR Calendar
  • Email Alerts
Oct 21, 2022 7:00am EDT

Matinas BioPharma to Present at the ThinkEquity Annual Global Investment Conference

Oct 19, 2022 7:10am EDT

Matinas BioPharma Announces Infectious Diseases Society of America (IDSA) has Selected the EnACT Phase 2 Trial Abstract of MAT2203 as its Outstanding Abstract and IDSA Awardee For IDWeek 2022

Oct 12, 2022 7:00am EDT

Matinas BioPharma to Present New MAT2203 (Oral Amphotericin B) Data During IDWeek 2022

Sep 21, 2022 7:00am EDT

Matinas BioPharma Announces Chairman Succession Plan

Sep 07, 2022 7:00am EDT

Matinas BioPharma to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 11, 2022 6:30am EDT

Matinas BioPharma Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

Aug 01, 2022 7:00am EDT

Matinas BioPharma to Participate in the BTIG Biotechnology Conference

Jul 28, 2022 4:15pm EDT

Matinas BioPharma to Webcast Conference Call Discussing Second Quarter 2022 Financial and Operational Results on August 11, 2022

Jul 25, 2022 6:30am EDT

Matinas BioPharma Announces Positive Opinion by the European Medicines Agency on Orphan Drug Designation for MAT2203 for the Treatment of Cryptococcosis

May 31, 2022 7:00am EDT

Matinas BioPharma to Present at the LD Micro Invitational XII Conference

RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...24
    Next
    Matinas BioPharma Holdings, Inc.

    Science

    • LNC PLATFORM
    • MAT2203
    • MAT2501

    Investors

    • COMPANY PROFILE
    • STOCK DATA
    • ANALYST COVERAGE
    • GOVERNANCE
    • PRESS RELEASES
    • EVENTS
    • PRESENTATIONS
    • SEC FILINGS

    Company

    • OVERVIEW
    • OUR TEAM
    • NEWS
    • CAREERS
    • CONTACT US

    Register for updates

    Follow Us

    LinkedIn facebook twitter
    © 2023 Matinas BioPharma Holdings, Inc. All Rights Reserved.